TAS::75 0849::TAS TARGETED PHOTOTHERMAL ABLATION OF MELANOMA

TAS::75 0849::TAS 黑色素瘤靶向光热消融术

• 批准号: 8165869
• 负责人: Glenn P Goodrich
• 金额: $ 20万
• 依托单位: NANOSPECTRA BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-24 至 2011-06-23
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8165869
• 关键词: Ablation; Cutaneous Melanoma; Devices; Disease; Family suidae; Gold; In Vitro; Laboratory Study; Lasers; Lesion; Magnetic Resonance; Melanocortin 1 Receptor; Metastatic Lesion; Metastatic malignant neoplasm to brain; Modeling; Monitor; Nanosphere; Neoplasm Metastasis; Normal tissue morphology; Patients; Phase; Procedures; Techniques; Temperature; Treatment Failure; innovation; lymph nodes; melanoma; minimally invasive; mouse model; nanoparticle; pre-clinical; response

We propose to develop a commercial product and procedure for the photothermal ablation of melanoma, including metastases, using targeted, near-infrared absorbing nanoparticles illuminated using a percutaneous laser energy delivery. This approach has been successfully demonstrated in a mouse model, and this proposal will extend the proof of feasibility into a spontaneous melanoma pig model. If successful , the Phase II proposal would conduct the necessary preclinical, in vitro and laboratory studies for an Investigational Device Exemption filing with FDA. Melanoma is characterized by a high capacity for invasion and metastasis. In-transit metastases, lymph node metastases, and brain metastases are serious problems in patients with this disease. Despite the application of various treatment approaches for in-transit metastases and brain metastases, the rate of treatment failure remains high. There is a critical need for innovative, minimally invasive techniques that can successfully target and treat metastatic lesions,while exerting minimal effects on surrounding normal tissue.

我们建议开发一种商业产品和程序，用于黑色素瘤的光热消融，包括转移瘤，使用靶向，近红外吸收纳米粒子，使用经皮激光能量输送照射。该方法已在小鼠模型中成功证明，该建议将可行性证明扩展到自发性黑色素瘤猪模型中。如果成功，II期提案将进行必要的临床前、体外和实验室研究，以向FDA提交研究器械豁免申请。黑色素瘤具有侵袭和转移能力强的特点。转运转移、淋巴结转移和脑转移是本病患者的严重问题。尽管转运转移和脑转移采用了多种治疗方法，但治疗失败率仍然很高。迫切需要创新的微创技术，能够成功地靶向和治疗转移性病变，同时对周围正常组织施加最小的影响。